High-throughput mutational screening adds clinically important information in myelodysplastic syndromes and secondary or therapy-related acute myeloid leukemia.

Karimi M, Nilsson C, Dimitriou M, Jansson M, Matsson H, Unneberg P, Lehmann S, Kere J, Hellström-Lindberg E

Haematologica 100 (6) e223-e225 [2015-06-00; online 2015-03-15]

Mutation Analysis Facility (MAF)

NGI Stockholm (Genomics Applications)

NGI Stockholm (Genomics Production)

QC bibliography QC xrefs

PubMed 25769547

DOI 10.3324/haematol.2014.118034

Crossref 10.3324/haematol.2014.118034

haematol.2014.118034

pmc PMC4450634